Brook Baker, a law pro­fessor at North­eastern Uni­ver­sity in Boston, calls this argu­ment a “topsy-​​turvy” inter­pre­ta­tion of so-​​called national treatment.

Under the logic of Eli Lilly’s investor-​​state claim, for­eign investors’ expec­ta­tions have become unbound,” Prof. Baker writes in a recent issue of Invest­ment Treaty News. “Eli Lilly hitches its invest­ment expec­ta­tion to the best deal on [intel­lec­tural prop­erty] achieved any­where [in the world].”

Read the article at The Globe and Mail →